Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ471,5472-0,42
KB5865871,73
PKN53,4253,44-0,89
Msft0,64
Nokia3,4143,421,11
IBM0,12
Daimler AG56,5556,570,89
PFE1,92
27.11.2020 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 27.11.2020
Viral Genetics Inc, Ordinary, US 'Other OTC' and Grey Market (VRALD.PK, US Other OTC (Pink Sheets))
Závěr k 27.11.2020 Změna (%) Změna (USD) Objem obchodů (ks)
0,0073 -26,56 0,00 454 668
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.11.2020
Popis společnosti
Obecné informace
Název společnostiVG Life Sciences Inc
TickerVGLS
Kmenové akcie:Ordinary Shares
RICVGLS.PK
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2014
Poslední známé čtvrtletní výsledky30.09.2015
Počet zaměstnanců k 31.12.2006 7
Akcie v oběhu k 30.09.2020 129 927 747
MěnaUSD
Kontaktní informace
UlicePO Box 1020
MěstoSOUTH PASADENA
PSČ91031-1020
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 058 799 000
Fax13026365454

Business Summary: VG Life Sciences Inc. is a biotechnology company. The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.
Financial Summary: BRIEF: For the nine months ended 30 September 2015, VG LifeSciences Inc revenues was not reported. Net loss decreased33% to $3.9M. Lower net loss reflects Interest expensedecrease of 33% to $1.4M (expense), Legal and Professionaldecrease of 63% to $403K (expense), Research anddevelopment decrease of 53% to $463K (expense). BasicEarnings per Share excluding Extraordinary Items increasedfrom -$0.21 to -$0.06.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.11.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Founder, Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Vice President - Research & Development, SecreHaig Keledjian5401.04.201601.01.1995